Akyso Therapeutics Expands Pipeline with New NIH Grant for Buprenorphine Implant Following Successful Phase 1a Trial of Naltrexone Implant
Akyso Therapeutics, a privately held biotechnology company developing long-acting subcutaneous drug delivery systems, today announced two major milestones: (1) the successful completion of its first-in-human Phase 1a clinical trial of iSTEP-N®, a bioabsorbable extended-release naltrexone implant for opioid use disorder (OUD) engineered to delivery naltrexone for 12 months following a single, simple, in office treatment, and (2) the receipt of $15 million in federal funding from the National Institute on Drug Abuse (NIDA) to develop a parallel12 month buprenorphine-based implant (iSTEP-B®) for OUD.
